Assessment of Low-Density Lipoprotein Cholesterol (LDL-C) Target Attainment in High-Risk Patients Receiving Statin Plus Ezetimibe Therapy: A Retrospective Cross-Sectional Study.

Cureus · 2025 · PMC12351352 · PMID 40821267

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although our comparison of atorvastatin- and rosuvastatin-based combinations did not reach statistical significance, previous data suggest a modest LDL-C benefit with atorvastatin, aligning with 2019 ESC/EAS recommendations for aggressive lipid targets and adjunctive therapies in very high-risk patients with uncontrolled lipids [ 16 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.